Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS

May 14th 2014

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

Discovery Dilemma: Narrow "Superiority" Standard Is an Inferior Way to Evaluate Novel Therapies

February 27th 2014

The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.

Dr. Keedy Discusses Imaging Biomarkers in Osteosarcoma

January 6th 2014

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

Novel Imaging Identifies Changes in Osteosarcoma Earlier in Treatment

December 23rd 2013

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

Updated Results Confirm Aldoxorubicin Superiority in STS

December 19th 2013

Aldoxorubicin demonstrated significant benefit to progression-free survival (PFS) compared with doxorubicin in patients with first-line, metastatic, locally advanced or unresectable soft tissue sarcomas

Early Data Show Patients With STS May Benefit From Belinostat

November 26th 2013

Final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial analyzing belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) demonstrated that the novel agent could provide benefit in this space

Aldoxorubicin More Effective Than Doxorubicin in Soft Tissue Sarcomas

November 22nd 2013

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.

Eribulin Shows Promise in Pediatric Sarcomas

November 21st 2013

Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.

Dr. Keedy on Regorafenib for the Treatment of GIST

November 12th 2013

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Promising TH-302 Results Accelerate Sarcoma Study

September 25th 2013

The list of agents currently available to treat soft-tissue sarcoma is rather short, with no drugs being approved on the basis of an improvement in overall survival in approximately 20 years.

Combination of Cixutumumab and Temsirolimus Demonstrates Improved Progression-Free and Encouraging Overall Survival for Bone and Soft Tissue Sarcoma

August 29th 2013

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.

Dr. Van Tine on Identifying Biomarkers in Sarcomas

August 12th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Dr. Van Tine on Arginine Deiminase for Sarcomas

June 11th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma

May 29th 2013

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

Imatinib Therapy Matures: GIST Research Sheds Light on Mutations, Drug Levels

March 26th 2013

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Palifosfamide Trial Reaches Target for PFS Events

February 12th 2013

The phase III PICASSO 3 trial examining palifosfamide plus doxorubicin in metastatic soft tissue sarcoma has reached its goal for progression-free survival events.

Surgery Following Imatinib Boosts Survival for GIST Patients

January 23rd 2013

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment

November 19th 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.